论文部分内容阅读
为探讨重组 (酵母 )乙型肝炎 (乙肝 )疫苗对成人的免疫效果及安全性 ,在辽宁省北票市部分学校选择一般健康状况良好 ,乙肝病毒表面抗原 (HBsAg)与抗体 (抗 HBs)、乙肝病毒核心抗体 (抗 HBc)三项指标均为阴性 ,体温正常 ,2 2～ 5 8岁的教师 12 4名 ,按 0、1、6个月免疫程序 ,接种北京生物制品研究所生产的重组 (酵母 )乙肝疫苗 ,每剂5 μg/ 0 5ml。结果显示 :免疫后 3、7、12、2 4、36个月时 ,抗 HBs阳转率分别为 35 0 %、83 3%、6 9 6 %、32 7%、2 0 8% ,差异有非常显著的统计学意义 (χ2 =117 6 9,P <0 0 1) ;抗 HBs几何平均滴度 (GMT)分别为 12 6 3mIU/ml、4 0 2 0 4mIU/ml、70 2 8mIU/ml、2 0 2 8mIU/ml、12 0 7mIU/ml,差异有非常显著的统计学意义 (F =5 71,P <0 0 1) ;抗 HBs阳转率及GMT均在免疫后 7个月时达到高峰 ,以后又急剧下降 ;免疫后各月女性抗 HBs阳转率和GMT均高于男性 ,但抗 HBsGMT仅在免疫后 3个月时二者之间的差异有非常显著的统计学意义 (t=3 0 0 ,P <0 0 1) ;<35岁组的抗体阳转率高于≥ 35岁组 ,但仅在免疫后 12个月时二者之间的差异有非常显著的统计学意义(χ2 =7 2 5 ,P <0 0 1) ;该两个年龄组间的抗 HBsGMT差异无显著的统计学意义 (P >0
In order to investigate the immunogenicity and safety of recombinant (yeast) hepatitis B (HBV) vaccine in adults, some schools in Beipiao, Liaoning Province, selected for their good general health status, hepatitis B virus surface antigen (HBsAg) and anti-HBs, Hepatitis B virus core antibody (anti-HBc) three indicators were negative, normal body temperature, 12 2 to 5 8-year-old teacher 12 4, according to 0,1,6 months of immunization programs, vaccination Beijing Institute of Biological Products recombinant (Yeast) Hepatitis B vaccine, 5 μg / 0 5 ml per dose. The results showed that the anti-HBs positive rates were 35 0%, 83 3%, 69 6%, 32 7% and 28 0% at 3, 7, 12, 24 and 36 months after immunization (Χ2 = 117 6 9, P <0.01). The geometric mean titers of anti-HBs were 12 6 3mIU / ml, 4 0 2 0 4mIU / ml and 70 2 8mIU / ml respectively , 2 0 2 8mIU / ml, 12 0 7mIU / ml, the difference was statistically significant (F = 5 71, P 0 01); anti-HBs positive rate and GMT were 7 months after immunization Reached a peak and dropped sharply thereafter. The positive rate of anti-HBs and GMT of women in each month after immunization were significantly higher than those of men, but there was a significant difference between the two anti-HBsGMT only at 3 months after immunization ( t = 300, P <0.01). The antibody positive rate in 35-year-old group was higher than that in 35-year-old group. However, there was a significant difference between the two groups only at 12 months after immunization (Χ2 = 7 2 5, P <0.01). There was no significant difference in anti-HBsGMT between the two age groups (P> 0